Myeloma (excluding monoclonal gammopathy of undetermined significance (MGUS)) |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating myeloma. |
AL amyloidosis |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating AL amyloidosis. |
Chronic B-cell lymphoproliferative disorders (chronic lymphocytic leukaemia, follicular lymphoma) |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating B-cell lymphoproliferative disorders including all B-Cell lymphomas and lymphomas where clinical coding is ambiguous to the nature of the lymphoma. |
Myelodysplastic syndrome (MDS) |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating myelodysplastic syndrome (MDS). |
Chronic myelomonocytic leukaemia (CMML) |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating chronic myelomonocytic leukaemia (CMML). |
Myelofibrosis |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating myelofibrosis. |
All people with sickle cell disease |
GPES, GDPPR, HES |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have ever had a clinical code in their medical records indicating sickle cell anaemia. |
Individuals with non-malignant haematological disorders (for example, aplastic anaemia or paroxysmal nocturnal haemoglobinuria) receiving B-cell depleting systemic treatment (for example, anti-CD20, anti-thymocyte globulin (ATG) and alemtuzumab) within the last 12 months |
GPES, GDPPR |
All people whose age equals 12 years minus therapeutic window minus 1 day or above who have had a clinical code in their medical records indicating a B-cell depleting therapy treatment within the last 12 months. |
People with thalassaemia or rare inherited anaemia with severe cardiac iron overload (T2 * less than 10ms on magnetic resonance imaging) or severe to moderate iron overload (T2 * greater than or equal to 10ms on magnetic resonance imaging) plus an additional co-morbidity of concern (for example, diabetes, chronic liver disease or severe hepatic iron load on MRI) |
|
Non-digital pathway |